{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:49:05Z","timestamp":1767034145061},"reference-count":47,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,27]],"date-time":"2006-07-27T00:00:00Z","timestamp":1153958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2006,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Statins (3\u2010hydroxymethylglutaryl\u2010coenzyme A reductase inhibitor) are widely used to treat hypercholesterolemia. They are generally well tolerated, but myotoxic effects have been reported and the corresponding mechanisms are still a matter of debate. The aim of the present study was to determine whether impairment of calcium homeostasis and\/or mitochondrial impairment could account for the adverse effects of statins in skeletal muscle.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eleven patients with increased creatine kinase levels and myalgias after statin treatment were evaluated using in vitro contracture tests (IVCTs), histology, and <jats:sup>31<\/jats:sup>P magnetic resonance spectroscopy (<jats:sup>31<\/jats:sup>P\u2010MRS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IVCT results were abnormal in 7 of the 9 patients, indicating an impaired calcium homeostasis. The <jats:sup>31<\/jats:sup>P\u2010MRS investigation disclosed no anomaly at rest, and the aerobic function assessed during the postexercise recovery period was normal. On the contrary, the pH recovery kinetics was significantly slowed down as indicated by a reduced proton efflux, which could be ultimately linked to a failure of calcium homeostasis. Overall, our observations indicate a normal mitochondrial function and raise the possibility that statins may unmask a latent pathology involving an impairment of calcium homeostasis such as malignant hyperthermia (MH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In case of susceptibility to MH, statins treatment must be administered with caution, and signs of adverse effects should be checked.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.22100","type":"journal-article","created":{"date-parts":[[2006,7,27]],"date-time":"2006-07-27T19:46:53Z","timestamp":1154029613000},"page":"551-557","source":"Crossref","is-referenced-by-count":51,"title":["In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin\u2010induced adverse effects"],"prefix":"10.1002","volume":"55","author":[{"given":"S.","family":"Guis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Figarella\u2010branger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nicoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Le Fur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kozak\u2010Ribbens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Pellissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Cozzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Amabile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bendahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91755-8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2003.70"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1997.03550040069040","article-title":"Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials","volume":"278","author":"Hebert PR","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A289"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022060-00003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1681"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10228"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2003.11.002"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2003.10.013"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11013"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003643-200407000-00013"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00711-2"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(89)90112-3"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.22.8928"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326010-00002"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-7-200210010-00009"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2003.08.013"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb03948.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.22.8931"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90129-D"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90266-X"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89180-1"},{"key":"e_1_2_6_25_2","first-page":"258","article-title":"Statin myopathies: pathophysiologic and clinical perspectives","volume":"24","author":"Baker SK","year":"2001","journal-title":"Clin Invest Med"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200211000-00002"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/56.11.1267"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00062-7"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199801000-00017"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.1940080207"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2001.00901.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf163"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1042\/bst019207s"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.1998.935bg.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2112"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.93.279"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704306"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.02.070"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91108-2"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000154790.42283.a1"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.6.1203"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400614"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194398"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/66.5.541"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.1910150109"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00106-1"},{"key":"e_1_2_6_48_2","first-page":"23","article-title":"Drug\u2010induced myopathies: an overview of the possible mechanisms","volume":"57","author":"Owczarek J","year":"2005","journal-title":"Pharmacol Rep"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.22100","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.22100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T23:44:08Z","timestamp":1697154248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.22100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,27]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8,15]]}},"alternative-id":["10.1002\/art.22100"],"URL":"https:\/\/doi.org\/10.1002\/art.22100","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,27]]}}}